PR96197

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire=KYODO JBN/--

   Excelra, a leading global data and digital insights organization, today

announced a partnership with HotSpot Therapeutics, Inc., a biotechnology

company pioneering the discovery and development of small molecule allosteric

therapies for the treatment of cancer and autoimmune diseases. HotSpot

Therapeutics plans to deploy data from Excelra's flagship product GOSTAR toward

select protein targets to augment its allosteric inhibitor candidate pipeline.

   The partnership aims to enhance HotSpot's drug discovery and development

efforts by incorporating GOSTAR's high-quality, annotated datasets into

HotSpot's machine learning (ML) and artificial intelligence (AI) models. With

the integration of GOSTAR data, HotSpot will continue to advance the discovery

and development of small molecule therapy candidates directed toward allosteric

targets that have been difficult to drug or undruggable with traditional small

molecule approaches.

   GOSTAR provides a unique 360 degrees view of over 8 million small molecules

and captures the most up-to-date view of the chemical space with information on

chemical structures and their biological properties, including binding, in

vitro, in vivo, ADME, toxicology, and physicochemical properties. The content

in GOSTAR is meticulously curated with a proprietary QMS-ISO-certified process.

   "Partnering with HotSpot Therapeutics allows for an exciting application of

hit mining, as it combines AI/ML models and structure-based algorithms to

accelerate both hit identification and chemical diversification in the field of

allostery," said Norman Azoulay, Director of Scientific Products, Excelra.

   "HotSpot's Smart AllosteryTM drug discovery platform has delivered a

pipeline of small molecule inhibitor candidates directed toward difficult to

drug or yet to be drugged targets in cancer and autoimmune disease," said

Geraldine Harriman, Ph.D., Co-Founder and Chief Scientific Officer of HotSpot

Therapeutics. "Our partnership with Excelra has the potential to expand a

portion of HotSpot's AI-enabled capabilities, allowing for the further

advancement of our pipeline of targets with identified natural hotspots, as

well as the design of novel allosteric modulators."

   About Excelra and GOSTAR

   Excelra's data and digital insights empower innovation in life sciences from

discovery to market. The Excelra edge comes from harmonizing heterogeneous data

sets and applying innovative bioinformatics know-how and technologies to

accelerate drug discovery and development with reliable and actionable

insights. Excelra's GOSTAR is available as an application for users to seek and

discover compounds. In addition, it is offered via APIs and as a downloadable

dataset to power in-house libraries and machine learning models.

   For more information about GOSTAR, visit: www.gostardb.com

[https://www.gostardb.com/]

   HotSpot Therapeutics is targeting naturally occurring pockets on certain

proteins that it refers to as "natural hotspots" that are decisive in

controlling cellular protein function. Largely unexploited by industry, these

pockets have significant potential for drug discovery and provide for the

systematic design of highly potent and selective small molecules that exhibit

novel pharmacology. The company's proprietary Smart Allostery™ platform

utilizes computational approaches and AI-driven data mining of large and highly

diverse data sets to identify natural hotspots, integrated with a tailored

pharmacology toolkit and bespoke chemistry which the company believes will

enable rapid delivery of superior hotspot-targeted small molecules. HotSpot has

established a pipeline of differentiated allosteric small molecules for the

treatment of cancer and autoimmune diseases. To learn more, visit:

https://www.hotspotthera.com  

   For media inquiries, contact:

   Jigesh Shah

   Jigesh.shah@excelra.com

   Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg

   Source: Excelra Knowledge Solutions Pvt Ltd